{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:30:06Z","timestamp":1740173406679,"version":"3.37.3"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.tranon.2024.102133","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:43:37Z","timestamp":1727678617000},"page":"102133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8165-7914","authenticated-orcid":false,"given":"Fang","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yandong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyun","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2024.102133_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2024.102133_bib0002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cam4.4433","article-title":"Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China","volume":"11","author":"Yuan","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.tranon.2024.102133_bib0003","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tranon.2024.102133_bib0004","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1200\/JCO.21.02566","article-title":"Anal Cancer: emerging Standards in a Rare Disease","volume":"40","author":"Eng","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102133_bib0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2024.102133_bib0006","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1288331","article-title":"Human papilloma virus load and PD-1\/PD-L1, CD8(+) and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy","volume":"6","author":"Balermpas","year":"2017","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.tranon.2024.102133_bib0007","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tranon.2024.102133_bib0008","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.102133_bib0009","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(24)00081-0","article-title":"Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study","volume":"25","author":"Kim","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.102133_bib0010","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.102133_bib0011","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends. Immunol."},{"key":"10.1016\/j.tranon.2024.102133_bib0012","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non\u2013small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102133_bib0013","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2019.37.15_suppl.8511","article-title":"Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer","volume":"37","author":"Jabbour","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102133_bib0014","article-title":"Neoadjuvant PD-1 blockade combined with chemotherapy followed by concurrent immunoradiotherapy in locally advanced anal canal squamous cell carcinoma patients: antitumor efficacy","volume":"12","author":"Xiao","year":"2021","journal-title":"Safety .Biomarker Analysis. Front. Immunol."},{"key":"10.1016\/j.tranon.2024.102133_bib0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.102133_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/oncolo\/oyab006","article-title":"Definitive intensity-modulated chemoradiation for anal squamous cell carcinoma: outcomes and toxicity of 428 patients treated at a single institution","volume":"27","author":"Holliday","year":"2022","journal-title":"Oncologist."},{"key":"10.1016\/j.tranon.2024.102133_bib0017","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1186\/s12885-022-09729-4","article-title":"Prognostic factors for patients with anal cancer treated with conformal radiotherapy-a systematic review","volume":"22","author":"Theophanous","year":"2022","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.tranon.2024.102133_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.tranon.2024.102133_bib0019","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.clon.2021.04.015","article-title":"Multicentre investigation of prognostic factors incorporating p16 and tumour infiltrating lymphocytes for anal cancer after chemoradiotherapy","volume":"33","author":"Wakeham","year":"2021","journal-title":"Clin. Oncol. (R. Coll. Radiol)"},{"key":"10.1016\/j.tranon.2024.102133_bib0020","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2024.102133_bib0021","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2024.102133_bib0022","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324002602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324002602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:32:26Z","timestamp":1739323946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523324002602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"alternative-id":["S1936523324002602"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102133","relation":{},"ISSN":["1936-5233"],"issn-type":[{"type":"print","value":"1936-5233"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. CCBYLICENSE","name":"copyright","label":"Copyright"}],"article-number":"102133"}}